Stock price performance of Achillion Pharmaceuticals, Inc. is analyzed for various periods using several stock trading signals. The stock price have dropped -7.49% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -51.19% . Looking at the past 52 week period, the stock price is down -31.65% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of Achillion Pharmaceuticals, Inc. has a negative value of -46.5 compared to overall market performance. For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a 20-day Moving Average of 2.67% and the 50-Day Moving Average is 3.57%.The 200 Day SMA reached 43.03%
Achillion Pharmaceuticals, Inc. is having a Relative Strength Index of 56.42 which indicates the stock is not yet over sold or over bought based on the technical indicators. Stocks of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) rallied by 5.62% during the past week but lost 2.92% on a 4-week basis. The company has outperformed the S&P 500 by 5.5% in the past week but underperformed the index by 3.79% in the last 4 weeks.
Company has reported several Insider transactions to the SEC, on Dec 23, 2016, Jason S Fisherman (director) purchased 10,000 shares at 3.96 per share price.On Dec 5, 2016, Martha E Manning (EVP, General Counsel) purchased 2,500 shares at 4.09 per share price.On Dec 5, 2016, Joseph Truitt (Chief Commercial Officer) purchased 3,500 shares at 4.06 per share price.
Achillion Pharmaceuticals Last issued its quarterly earnings results on Aug 4, 2016. The company reported $-0.14 EPS for the quarter, beating the analyst consensus estimate by $ 0.01. Analyst had a consensus of $-0.15.During the same quarter in the previous year, the company posted $-0.25 EPS.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Achillion Pharmaceuticals was Initiated by Ladenburg Thalmann on Feb 2, 2017 to Buy, Price Target of the shares are set at $10.
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) : On Friday heightened volatility was witnessed in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) which led to swings in the share price. The stock opened for trading at $4.24 and hit $4.36 on the upside , eventually ending the session at $4.32, with a gain of 2.61% or 0.11 points. The heightened volatility saw the trading volume jump to 1,775,128 shares. The 52-week high of the share price is $10.06 and the company has a market cap of $590 million. The 52-week low of the share price is at $3.78 .
ACHILLION PHARMACEUTICALS, INC. is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The companys proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease — HIV, hepatitis and resistant bacterial infections. Achillion sees significant competitive advantages in developing anti-infective drugs compared to developing drugs in other therapeutic areas. The emergence of drug resistance seen with current antiviral and antibacterial therapies creates a continuing need for new drugs, providing a large and growing potential business opportunity. In addition, development cycle times tend to be somewhat shorter in infectious disease than other therapeutic areas, and early drug development results tend to be more predictive of longer term results.